top of page
Join Eyecelerator at AAO 2023 in San Francisco

Eyecelerator @ AAO 2023

San Francisco Marriott Marquis | Thursday, November 2


*Panels are in development and speakers are subject to change.

Registration + Networking Breakfast

7:00 – 8:00 a.m.

Registration and breakfast

Welcome Remarks

8:00 – 8:10 a.m.

  • Stephen D. McLeod, MD, CEO, American Academy of Ophthalmology 

  • Allen C. Ho, MD, Retina Program Director

  • Gil Kliman, MD, Program Director

S1: The Year in Review

8:10 – 8:45 a.m.

Overview and discussion of key trends and events in the 2023 ophthalmology marketplace.

Moderators: Gil Kliman, MD and Jim Mazzo 


Market Overview: Kristen Harmon Ingenito, Market Scope

Public and Private Markets: Andrew Gitkin, Vice Chairman, Health Care Investment Banking, Raymond James


  • Sebastien Allard, VP, Corporate Development Strategy, Alcon

  • Jay S. Duker, MD, CEO, Eyepoint Pharmaceuticals

  • Adrienne L. Graves, PhD, Former Board Chair, IvericBio

  • Wende Hutton, MBA, General Partner, Canaan Partners

S2: Industry’s Role in Nurturing Robust Innovation

8:45 – 9:30 a.m.

Significant financial commitments are required for FDA clearance of new products. As global strategics increasingly delay investment, how can pioneering companies persevere?

Moderators: Zaina Al-Mohtaseb, MD and Nicole R. Fram, MD


  • Andrew Gitkin, Vice Chairman, Health Care Investment Banking, Raymond James

  • Kendra Hileman, Head of Instrumentation R&D, Alcon

  • Sean Ianchulev, Eyenovia 

  • Philip Kowalczyk, VP, Business Development, Johnson & Johnson Vision

  • Mariam Maghribi, Chief Business Officer, Shifamed

  • Ramin Valian, VP, US Eyecare, Allergan, an AbbVie Company

Networking Break 

9:30 – 10:00 a.m.

Networking Break –  Marriott Grand Ballroom Foyer

S3: Mapping the Future of Geographic Atrophy

10:00 – 11:00 a.m.

With the approval of two new drugs and multiple other pathways under investigation in human trials, new treatments for GA have the potential to revolutionize patient care. 

Moderators: Robert L. Avery, MD and Aleksandra V. Rachitskaya, MD 


  • ONL Therapeutics: David Esposito, CEO

  • Annexon Biosciences: Douglas Love, Esq., President & CEO

  • Lineage Cell Therapeutics: Brian Culley, CEO 

  • Aviceda Therapeutics: Mohamed A. Genead, MD, Co-Founder, CEO & President

  • Apellis: Cedric Francois, MD, CEO

  • Iveric Bio: Erin Henry, VP, Strategy & Innovation


  • Wiley Chambers, MD, Director, Division of Ophthalmology, FDA  

  • Cedric Francois, MD, CEO, Apellis

  • Erin Henry, VP, Strategy & Innovation, Iveric Bio

  • Daniel Lyons, PhD, CFA, Janus Henderson Investors

  • Namrata Saroj, OD, Principal, All Eyes Consulting 

The Winning Pitch Challenge

11:00 – 11:45 a.m. 

Back by popular demand! The Shark Tank-style competition features pitches from three early-stage ophthalmology innovators, with judges and the audience deciding who will take home cash prizes worth $45,000.

Moderators: Vance Thompson, MD and Robert Warner 



  • Niki Bayat, PhD – AesculaTech Humidifeye 
    Mentor: Leonard Borrmann, PharmD

  • Oussama Boundaoui, MD – Regenoptics Tamponading Hydrogel  
    Mentor: Shravanthi Reddy, PhD 

  • David Kleinman, MD – Calm Water Therapeutics, LLC
    Mentor: Robert Dempsey 



  • Adrienne L. Graves, PhD, Former Board Chair, Iveric Bio 

  • Richard L. Lindstrom, Founder, Minnesota Eye Associates

  • Angela Macfarlane, CEO, Perceive

  • Jim Mazzo, Executive Chairman, Neurotech Pharmaceuticals  

Networking Lunch

11:45 a.m. – 12:30 p.m.

Enjoy a bite to eat with your colleagues.

Presenting Company Showcases

12:30 – 2:15 p.m. 

Forty companies present innovative new treatments, products and services. Breakout rooms will operate simultaneously for each segment. Follow these links for showcase schedules:

Retina Showcase: Nob Hill Room

Anterior Segment Showcase: Salons 11 – 14

Glaucoma + Digital Showcase: Salons 3 – 5


Networking Break

2:15 – 2:45 p.m. 

Networking Break 

S4: Key Ingredients of Successful Innovation

2:45 – 3:15 p.m. 

Listen and learn from strategics, start-ups and biotech investors on what it takes to successfully get ophthalmic innovations to market and efficiently improve quality of life for patients.

Moderators: Allen C. Ho, MD and Robert L. Avery, MD 



  • Anthony P. Adamis, MD, Chief Scientific Officer, EyeBio
    David Bingaman, Chief Development Officer, Ora
  • Christoper Brittain, MBBS, Head of Global Development, Genentech
  • Wiley Chambers, MD, Director, Division of Ophthalmology, FDA
  • Lori-Ann Christie, PhD, Principal, Visionary Ventures
  • Steve Pakola, MD, Chief Medical Officer, REGENXBIO
  • Richard Small, CEO, Neurotech 
  • Robert Vitti, MD, Vice President, Regeneron

S5: Decoding the Viability of Artificial Intelligence

3:15 – 4:00 p.m.

Uncover the secrets of why some AI concepts spur vigorous investment while others struggle to gain traction. 

Moderators: Julie M. Schallhorn, MD, MS and Lejla Vajzovic, MD 

Keynote Speaker: 

The AI Gold Rush?  A Matter of Perception 

Khizer R. Khaderi, MD, MPH, Director, Stanford Human Perception Lab


  • AI – Generative: Vivek Natarajan, AI Researcher, Google  

  • AI – Screening: Kester Nahen, PhD, CEO Notal Vision 

  • AI – Image Analysis: Kaushal Solanki, Eyenuk   

  • AI – Big Pharma: Victor Chong, MD, Global Head of Retina, Janssen



  • Victor Chong, MD, VP, Global Head of Retina, Janssen

  • Malvenia Eydelman, MD, Director, FDA

  • Ranya Habash, MD, CEO, LifeLong Viion

  • Vivek Natarajan, AI Researcher, Google

  • Kester Nahen, PhD, CEO, Notal Vision 

S6: 10 Perspectives For Navigating Today’s Regulatory Landscape

4:00 – 4:45 p.m.

Examine the relevance of current Patient Reported Outcomes (PROs) and the feasibility of new draft guidance for retina treatments. 

Moderator:  Arsham Sheybani, MD and Charles Wykoff, MD, PhD


  • David S. Boyer, MD, Sr Partner, Retina Vitreous Associates 

  • Wiley Chambers, MD, Director, Division of Ophthalmology, FDA

  • Malvina Eydelman, MD, Director, CDFH/FDA

  • Gus Gazzard, MD, Director, Moorfields Eye Hospital

  • Chuck Hess, Global VP Commercial Development and Digital Health, Bausch + Lomb

  • Eris Jordan, OD, VP Global Clinical and Medical Affairs, Aurion Biotech

  • Gary D. Novack, PhD, President, PharmaLogic Development 

  • Steven C. Schallhorn, MD, Chief Medical Officer, Zeiss           

Closing Bell and People's Choice Awards

4:45 – 5:00 p.m. 

The program committee wraps the day with insights and People's Choice recognition.


  • Zaina Al-Mohtaseb, MD, Program Co-Chair

  • Robert L. Avery, MD, Program Co-Chair 

  • Gil Kliman, MD, Program Director


5:00 – 6:00 p.m. 

Enjoy refreshments and connect!

bottom of page